Efficacy and Safety APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

Details

Instance of

clinical trial

Start time

30 January 2020

End time

31 October 2021

Country

United States

Main subject

fluticasone, non-steroidal anti-inflammatory drug, antiasthmatic, anti-allergic agents, eosinophilic esophagitis, esophagitis

clinical trial phase

phase III clinical trial

minimum age

15

number of participants

120

research intervention

fluticasone

short name

FLUTE-2

study type

interventional study

title

Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects With Eosinophilic Esophagitis